Proteomics

Dataset Information

0

Neuroblastoma HLA class I Immunopeptidomics


ABSTRACT: We surveyed the immunopeptidome of neuroblastoma tumors to identify tumor-specific targets derived from non-mutated self proteins originating from core-regulatory circuit proteins.

INSTRUMENT(S): Orbitrap Fusion Lumos

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Primary Cell, Early Embryonic Cell, Kidney

DISEASE(S): Neuroblastoma

SUBMITTER: Mark Yarmarkovich  

LAB HEAD: John M. Maris

PROVIDER: PXD027182 | Pride | 2021-08-11

REPOSITORIES: Pride

altmetric image

Publications


The majority of oncogenic drivers are intracellular proteins, thus constraining their immunotherapeutic targeting to mutated peptides (neoantigens) presented by individual human leukocyte antigen (HLA) allotypes<sup>1</sup>. However, most cancers have a modest mutational burden that is insufficient to generate responses using neoantigen-based therapies<sup>2,3</sup>. Neuroblastoma is a paediatric cancer that harbours few mutations and is instead driven by epigenetically deregulated transcription  ...[more]

Similar Datasets

2022-09-22 | PXD024417 | Pride
2020-12-01 | PXD019258 | Pride
2022-05-31 | PXD033935 | Pride
2015-07-14 | PXD001904 | Pride
2015-07-14 | PXD001872 | Pride
2018-02-19 | PXD008984 | Pride
2023-02-27 | PXD033383 | Pride
2021-12-22 | PXD027859 | Pride
2023-03-11 | PXD037587 | Pride
2020-01-15 | PXD012797 | Pride